Jpmorgan Chase & Co »

Apogee Therapeutics shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Apogee Therapeutics (APGE) shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Apogee Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Apogee Therapeutics held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Apogee Therapeutics by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2023-12-31 $644k 23k 27.94
2023-09-30 $282k 13k 21.30

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Apple Common (AAPL)
Amazon Common (AMZN)
Spdr S&p 500 Etf Trust Fund (SPY)
Nvidia Corporation Common (NVDA)
Meta Platforms Common (META)
Unitedhealth Group Common (UNH)
Vanguard Total Intl Bond Etf Fund (BNDX)
Alphabet Common (GOOG)
Eli Lilly & Co Common (LLY)
Mastercard Incorporated Common (MA)
Alphabet Common (GOOGL)
Abbvie Common (ABBV)
Vanguard Total Bond Market Fund (BND)
Tesla Common (TSLA)

View all positions for Jpmorgan Chase & Co

Top funds holding Apogee Therapeutics

VR Adviser
Fairmount Funds Management
RA Capital Management
Perceptive Advisors
Wellington Management Company
OrbiMed Advisors
Vanguard Group
Franklin Resources
T. Rowe Price Associates
Point72 Asset Management
Braidwell
Bank of America Corporation
Henderson Group
Dr. Jeffrey R. Jay, M.D.
Frazier Life Sciences Management

View all funds holding Apogee Therapeutics